US5045553A
(en)
*
|
1987-06-24 |
1991-09-03 |
Fujisawa Pharmaceutical Company, Ltd. |
Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
|
US4941457A
(en)
*
|
1989-08-17 |
1990-07-17 |
Olympus Optical Co., Ltd. |
Endoscope using an optical guide twisted on the tip side to have the visual field direction and curvature axis coincide with each other
|
IT1243745B
(it)
*
|
1990-10-17 |
1994-06-21 |
Vectorpharma Int |
Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
|
US5326566A
(en)
*
|
1991-05-17 |
1994-07-05 |
Bristol-Myers Squibb Company |
Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
|
US5990179A
(en)
*
|
1995-04-28 |
1999-11-23 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US5985316A
(en)
*
|
1995-04-28 |
1999-11-16 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
JP2004505886A
(ja)
|
2000-02-18 |
2004-02-26 |
スィーヴィー セラピューティクス インコーポレイテッド |
鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
|
WO2001062979A2
(en)
|
2000-02-23 |
2001-08-30 |
Cv Therapeutics, Inc. |
Dentification of partial agonists of the a2a adenosine receptor
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
EP1345606A4
(en)
*
|
2000-11-17 |
2005-02-09 |
Pharmacyclics Inc |
TEXAPHYRIN COORDINATION COMPOUNDS AND USES THEREOF
|
CA2430951A1
(en)
|
2000-12-07 |
2002-06-13 |
Cv Therapeutics, Inc. |
Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
AU2002359365B2
(en)
|
2001-11-09 |
2008-07-10 |
Gilead Sciences, Inc. |
A2B adenosine receptor antagonists
|
JP2005527502A
(ja)
*
|
2002-02-19 |
2005-09-15 |
シーブイ・セラピューティクス・インコーポレイテッド |
A1アデノシン受容体の部分的および全アゴニスト
|
US20030220344A1
(en)
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
EP2332540A1
(en)
*
|
2002-05-21 |
2011-06-15 |
Cv Therapeutics, Inc. |
Administration of ranolazine for the treatment of diabetes
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
CA2492855C
(en)
*
|
2002-07-29 |
2012-09-18 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging using a2a receptor agonists
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
CA2513529A1
(en)
|
2003-01-17 |
2004-08-19 |
Cv Therapeutics Inc. |
Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
|
DK1628663T3
(da)
*
|
2003-05-15 |
2010-03-08 |
Roskamp Res Llc |
Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
|
ES2383525T3
(es)
*
|
2003-11-05 |
2012-06-21 |
Sarcode Bioscience Inc. |
Moduladores de la adhesión celular
|
EP1802258A4
(en)
|
2004-09-13 |
2015-09-23 |
Chrono Therapeutics Inc |
BIOSYNCHRONE TRANSDERMAL MEDICINES
|
NZ589657A
(en)
|
2004-10-15 |
2012-06-29 |
Gilead Palo Alto Inc |
Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
|
EP1802317A2
(en)
*
|
2004-10-20 |
2007-07-04 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists
|
US20060111308A1
(en)
*
|
2004-11-16 |
2006-05-25 |
Wendye Robbins |
Methods and compositions for therapeutic treatment
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
WO2006119292A2
(en)
*
|
2005-04-29 |
2006-11-09 |
Henkin, Robert |
Methods for detection of biological substances
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
CA2609053C
(en)
|
2005-05-17 |
2017-04-25 |
Sarcode Corporation |
Compositions and methods for treatment of eye disorders
|
CA2612344A1
(en)
*
|
2005-06-16 |
2006-12-28 |
Cv Therapeutics, Inc. |
Prodrugs of a2b adenosine receptor antagonists
|
CA2613703A1
(en)
|
2005-06-28 |
2007-01-04 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
US20070072838A1
(en)
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
AU2007212542B2
(en)
|
2006-02-03 |
2013-01-31 |
Gilead Sciences, Inc. |
Process for preparing an A2A-Adenosine receptor agonist and its polymorphs
|
WO2007103776A2
(en)
*
|
2006-03-02 |
2007-09-13 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
EP2068850A1
(en)
*
|
2006-06-22 |
2009-06-17 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists in the treatment of ischemia
|
CA2653056A1
(en)
|
2006-07-27 |
2008-01-31 |
Cv Therapeutics, Inc. |
Aldh-2 inhibitors in the treatment of addiction
|
MX2009002299A
(es)
*
|
2006-09-01 |
2009-03-20 |
Cv Therapeutics Inc |
Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
EP2066232A1
(en)
*
|
2006-09-29 |
2009-06-10 |
Cv Therapeutics, Inc. |
Methods for myocardial imaging in patients having a history of pulmonary disease
|
JP2010505881A
(ja)
*
|
2006-10-05 |
2010-02-25 |
ギリアード・パロ・アルト・インコーポレイテッド |
ステアロイルCoAデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
WO2008086096A2
(en)
*
|
2007-01-03 |
2008-07-17 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
GB2448224B
(en)
|
2007-04-02 |
2010-09-01 |
Parkinson S Inst |
Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
|
US7662819B2
(en)
*
|
2007-04-09 |
2010-02-16 |
Gilead Palo Alto, Inc. |
Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
GB2463833B
(en)
*
|
2007-06-26 |
2012-02-08 |
Parkinson S Inst |
Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
CA2701620C
(en)
*
|
2007-10-05 |
2014-12-09 |
Alzheimer's Institute Of America, Inc. |
Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
|
US20100093810A1
(en)
*
|
2007-10-05 |
2010-04-15 |
Alzheimer's Institute Of America, Inc. |
Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
|
EP3797775A1
(en)
|
2007-10-19 |
2021-03-31 |
Novartis AG |
Compositions and methods for treatment of diabetic retinopathy
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
MX2010007418A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
JP2011511802A
(ja)
*
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
KR20100132999A
(ko)
*
|
2008-04-04 |
2010-12-20 |
길리애드 사이언시즈, 인코포레이티드 |
스테아로일 CoA 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
CN102065893A
(zh)
*
|
2008-04-15 |
2011-05-18 |
萨可德公司 |
Lfa-1拮抗剂向胃肠***的递送
|
ES2763703T3
(es)
*
|
2008-04-15 |
2020-05-29 |
Sarcode Bioscience Inc |
Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
|
JP2011518155A
(ja)
*
|
2008-04-15 |
2011-06-23 |
サーコード コーポレイション |
免疫関連障害の局所治療に使用するためのエアゾール化lfa−1アンタゴニスト
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8580801B2
(en)
*
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
US20100086483A1
(en)
*
|
2008-09-29 |
2010-04-08 |
Gilead Palo Alto, Inc. |
Method of multidetector computed tomagraphy
|
AU2009302241B2
(en)
*
|
2008-10-08 |
2015-10-29 |
Xgene Pharmaceutical Inc. |
GABA conjugates and methods of use thereof
|
US10098857B2
(en)
|
2008-10-10 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
|
US20100267752A1
(en)
*
|
2008-10-15 |
2010-10-21 |
Gilead Palo Alto, Inc. |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20100113514A1
(en)
|
2008-10-30 |
2010-05-06 |
Gilead Palo Alto, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
WO2010056527A2
(en)
|
2008-10-30 |
2010-05-20 |
Gilead Palo Alto, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
WO2010056919A2
(en)
*
|
2008-11-12 |
2010-05-20 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine prodrugs, conjugates and salts, and methods of use thereof
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
JP2012526848A
(ja)
*
|
2009-05-14 |
2012-11-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cns障害の治療のためのラノラジン
|
WO2010144611A2
(en)
*
|
2009-06-10 |
2010-12-16 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
CA2774715C
(en)
|
2009-07-27 |
2018-04-03 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
WO2011019752A2
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
US9562056B2
(en)
|
2010-03-11 |
2017-02-07 |
Gilead Connecticut, Inc. |
Imidazopyridines Syk inhibitors
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
EA201291274A1
(ru)
|
2010-06-30 |
2013-12-30 |
Джилид Сайэнс, Инк. |
Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии
|
CN103096977B
(zh)
|
2010-07-02 |
2017-02-15 |
吉利德科学公司 |
作为离子通道调节剂的稠杂环化合物
|
AU2011272782B2
(en)
|
2010-07-02 |
2014-11-27 |
Gilead Sciences, Inc. |
Apoptosis signal-regulating kinase inhibitors
|
EP2601609B1
(en)
|
2010-08-02 |
2017-05-17 |
Population Bio, Inc. |
Compositions and methods for discovery of causative mutations in genetic disorders
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG10201602752XA
(en)
|
2011-01-07 |
2016-05-30 |
Allergan Inc |
Melanin modification compositions and methods of use
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
BR112013022761B8
(pt)
|
2011-03-08 |
2023-01-17 |
3 V Biosciences Inc |
Compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
CA2834164A1
(en)
|
2011-05-10 |
2012-11-15 |
Gilead Sciences, Inc. |
Fused benzoxazinones as ion channel modulators
|
NO3175985T3
(da)
|
2011-07-01 |
2018-04-28 |
|
|
TWI478908B
(zh)
|
2011-07-01 |
2015-04-01 |
Gilead Sciences Inc |
作為離子通道調節劑之稠合雜環化合物
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
TWI468403B
(zh)
|
2011-08-30 |
2015-01-11 |
Gilead Sciences Inc |
用於治療成癮之aldh-2抑制劑
|
CA2849505A1
(en)
|
2011-09-21 |
2013-03-28 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US10221454B2
(en)
|
2011-10-10 |
2019-03-05 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
US11180807B2
(en)
|
2011-11-04 |
2021-11-23 |
Population Bio, Inc. |
Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
|
DK2812452T3
(da)
|
2012-02-09 |
2020-06-29 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8969588B2
(en)
|
2012-06-05 |
2015-03-03 |
Gilead Pharmasset Llc |
Solid forms of an antiviral compound
|
US9321749B1
(en)
|
2012-07-25 |
2016-04-26 |
Globavir Biosciences, Inc. |
Heterocyclic compounds and uses thereof
|
MX2015001098A
(es)
|
2012-07-25 |
2015-09-25 |
Sarcode Bioscience Inc |
Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
EP2895621B1
(en)
|
2012-09-14 |
2020-10-21 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
US10233495B2
(en)
|
2012-09-27 |
2019-03-19 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
NZ744567A
(en)
|
2012-11-01 |
2020-03-27 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
US20140120060A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
AU2013364070B2
(en)
|
2012-12-21 |
2016-10-27 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
TW201441216A
(zh)
|
2012-12-21 |
2014-11-01 |
Gilead Calistoga Llc |
肌醇磷酯3-激酶的抑制劑
|
WO2014105655A1
(en)
|
2012-12-24 |
2014-07-03 |
Neurogastrx, Inc. |
Methods for treating gi tract disorders
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
TWI530499B
(zh)
*
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
BR112015029969A2
(pt)
|
2013-05-30 |
2017-07-25 |
Infinity Pharmaceuticals Inc |
tratamento de câncer usando moduladores de isoformas quinase pi3
|
MX347988B
(es)
|
2013-06-14 |
2017-05-19 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-cinasa.
|
AU2014296184B2
(en)
|
2013-07-31 |
2017-04-27 |
Gilead Sciences, Inc. |
Syk inhibitors
|
WO2015051341A1
(en)
|
2013-10-03 |
2015-04-09 |
Araxes Pharma Llc |
Inhibitors of erk and methods of use
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2013406206B2
(en)
|
2013-11-26 |
2017-07-20 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
CN105764516A
(zh)
|
2013-12-04 |
2016-07-13 |
吉利德科学公司 |
治疗癌症的方法
|
JP2016540053A
(ja)
|
2013-12-05 |
2016-12-22 |
アセルタ ファーマ ビー.ブイ. |
Pi3k阻害剤とbtk阻害剤の治療的組み合わせ
|
SG11201604457XA
(en)
|
2013-12-19 |
2016-07-28 |
Gilead Sciences Inc |
Fused heterocyclic compounds as ion channel modulators
|
ES2708993T3
(es)
|
2013-12-23 |
2019-04-12 |
Gilead Sciences Inc |
Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
TW201613908A
(en)
|
2014-02-13 |
2016-04-16 |
Gilead Sciences Inc |
Solid forms of an ion channel modulator
|
WO2015126944A1
(en)
|
2014-02-18 |
2015-08-27 |
Henkin Robert I |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
US9775844B2
(en)
|
2014-03-19 |
2017-10-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015185998A2
(en)
|
2014-04-11 |
2015-12-10 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
US10040767B2
(en)
|
2014-05-15 |
2018-08-07 |
Peloton Therapeutics, Inc. |
Benzimidazole derivatives and uses thereof
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
KR20170012560A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
ES2750357T3
(es)
|
2014-06-13 |
2020-03-25 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa
|
PE20170268A1
(es)
|
2014-06-19 |
2017-04-21 |
Ariad Pharma Inc |
Compuestos de heteroarilo para la inhibicion de cinasa
|
US9844554B2
(en)
|
2014-06-24 |
2017-12-19 |
Neurogastrx, Inc. |
Prodrugs of metopimazine
|
SG11201610551TA
(en)
|
2014-07-14 |
2017-01-27 |
Gilead Sciences Inc |
Combinations for treating cancers
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
TW201618774A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
GB2558326B
(en)
|
2014-09-05 |
2021-01-20 |
Population Bio Inc |
Methods and compositions for inhibiting and treating neurological conditions
|
ES2881195T3
(es)
|
2014-09-26 |
2021-11-29 |
Gilead Sciences Inc |
Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
CN111888368B
(zh)
|
2014-10-21 |
2024-02-02 |
武田药品工业株式会社 |
5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
CN114146088A
(zh)
|
2015-01-28 |
2022-03-08 |
杜克大学 |
用于治疗神经精神类障碍的组合物及方法
|
US10213586B2
(en)
|
2015-01-28 |
2019-02-26 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
EP3267792A4
(en)
|
2015-03-11 |
2018-09-26 |
Peloton Therapeutics, Inc. |
Compositions for use in treating pulmonary arterial hypertension
|
WO2016144826A1
(en)
|
2015-03-11 |
2016-09-15 |
Peloton Therapeutics, Inc. |
Substituted pyridines and uses thereof
|
CN107428728A
(zh)
|
2015-03-19 |
2017-12-01 |
3-V生物科学股份有限公司 |
脂质合成的杂环调节剂
|
NZ738525A
(en)
|
2015-07-06 |
2019-03-29 |
Gilead Sciences Inc |
Cot modulators and methods of use thereof
|
US10858316B2
(en)
|
2015-07-10 |
2020-12-08 |
University Of Maryland, Baltimore |
Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017083488A1
(en)
|
2015-11-11 |
2017-05-18 |
Warner Babcock Institute for Green Chemistry |
Benzofuran derivatives for the treatment of cns and other disorders
|
US10316049B2
(en)
|
2015-12-17 |
2019-06-11 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
HUE052893T2
(hu)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Antifolát és BTK-gátló terápiás kombinációi
|
WO2017147328A1
(en)
|
2016-02-23 |
2017-08-31 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
CA3016081A1
(en)
|
2016-03-04 |
2017-09-08 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017218802A1
(en)
|
2016-06-15 |
2017-12-21 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
AU2017281222B2
(en)
|
2016-06-23 |
2022-06-16 |
The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) |
Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
|
US10059695B2
(en)
|
2016-06-30 |
2018-08-28 |
Gilead Sciences, Inc. |
Cot modulators and methods of use thereof
|
EP3512519A1
(en)
|
2016-09-14 |
2019-07-24 |
Gilead Sciences, Inc. |
Syk inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
WO2018075601A1
(en)
|
2016-10-18 |
2018-04-26 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018085833A2
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
|
WO2018085818A1
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018098491A1
(en)
|
2016-11-28 |
2018-05-31 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
JP7105797B2
(ja)
|
2016-11-28 |
2022-07-25 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
化合物及びその使用方法
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
WO2018129304A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
US11220524B2
(en)
|
2017-02-20 |
2022-01-11 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
WO2018152501A1
(en)
|
2017-02-20 |
2018-08-23 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160824A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160855A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
US11286233B2
(en)
|
2017-05-09 |
2022-03-29 |
Ambient Photonics, Inc. |
Stilbene derivatives for the treatment of CNS and other disorders
|
EP3641741B1
(en)
|
2017-06-19 |
2024-03-20 |
University of Maryland, Baltimore |
Microtubule polymerization inhibitor prodrugs and methods of using the same
|
EP3665179B1
(en)
|
2017-08-09 |
2021-06-09 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
TW202024061A
(zh)
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
WO2019040102A1
(en)
|
2017-08-22 |
2019-02-28 |
Gilead Sciences, Inc. |
THERAPEUTIC HETEROCYCLIC COMPOUNDS
|
US11331288B2
(en)
|
2017-09-14 |
2022-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conditioning irradiated tissue for increasing vascularity
|
US11752146B2
(en)
|
2017-09-28 |
2023-09-12 |
Medicon Pharmaceuticals, Inc. |
Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
CN111542525B
(zh)
|
2017-10-26 |
2023-06-27 |
普莱鲁德疗法有限公司 |
蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
|
EP3710599A1
(en)
|
2017-11-13 |
2020-09-23 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
KR102587510B1
(ko)
|
2018-02-15 |
2023-10-11 |
길리애드 사이언시즈, 인코포레이티드 |
피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
|
CA3090280A1
(en)
|
2018-02-16 |
2019-08-22 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
|
CA3091924A1
(en)
|
2018-03-02 |
2019-09-06 |
Oregon Health & Science University |
Amide prodrugs of small molecule nuclear receptor modulators
|
JP7328241B2
(ja)
|
2018-03-14 |
2023-08-16 |
プレリュード セラピューティクス,インコーポレイティド |
タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤
|
US10711007B2
(en)
|
2018-03-14 |
2020-07-14 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
WO2019196622A1
(zh)
|
2018-04-09 |
2019-10-17 |
威尚(上海)生物医药有限公司 |
具有穿过血脑屏障能力的5取代二氟哌啶化合物
|
WO2019219000A1
(en)
|
2018-05-14 |
2019-11-21 |
Xgene Pharmaceutical Inc. |
Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
|
AU2019279884A1
(en)
|
2018-05-29 |
2020-12-10 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|
MX2020012838A
(es)
|
2018-05-30 |
2021-07-16 |
Praxis Prec Medicines Inc |
Moduladores de los canales ionicos.
|
CA3103987C
(en)
|
2018-07-06 |
2023-08-01 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
KR102629921B1
(ko)
|
2018-07-06 |
2024-01-31 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
JP2021530523A
(ja)
|
2018-07-16 |
2021-11-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivの処置のためのカプシド阻害剤
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
HRP20221504T1
(hr)
|
2018-08-08 |
2023-03-31 |
Pml Screening, Llc |
Postupci procjene rizika od razvoja progresivne multifokalne leukoencefalopatije uzrokovane john cunningham virusom pomoću genetskog testiranja
|
AU2019329835A1
(en)
|
2018-08-27 |
2021-04-15 |
Spinogenix, Inc. |
Fascin binding compounds for spinogenesis
|
WO2020072377A1
(en)
|
2018-10-01 |
2020-04-09 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
JP7460644B2
(ja)
|
2018-10-31 |
2024-04-02 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物
|
CA3118919A1
(en)
|
2018-11-09 |
2020-05-14 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
MD3880654T2
(ro)
|
2018-11-19 |
2022-05-31 |
Global Blood Therapeutics Inc |
Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei
|
AU2019392904B9
(en)
|
2018-12-07 |
2022-12-22 |
University Of Maryland, Baltimore |
Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
|
CN113423684A
(zh)
|
2018-12-12 |
2021-09-21 |
速通医疗公司 |
新型拟甲状腺素药
|
EP3894416B1
(en)
|
2018-12-13 |
2022-11-09 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
WO2020123994A1
(en)
|
2018-12-14 |
2020-06-18 |
Prelude Therapeutics, Incorporated |
2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
|
EP3920906A4
(en)
|
2019-02-06 |
2023-07-12 |
Oregon Health & Science University |
COMPOUNDS RELATED TO BISPHOSPHONATES
|
JP2022521491A
(ja)
|
2019-02-13 |
2022-04-08 |
プレリュード・セラピューティクス・インコーポレイテッド |
タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤
|
US11339168B2
(en)
|
2019-02-22 |
2022-05-24 |
Kronos Bio, Inc. |
Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
JP2022521431A
(ja)
|
2019-02-25 |
2022-04-07 |
シーエイチディーアイ ファウンデーション,インコーポレーテッド |
変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
US11667606B2
(en)
|
2019-03-01 |
2023-06-06 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
CN114269340A
(zh)
|
2019-05-03 |
2022-04-01 |
普拉克西斯精密药物股份有限公司 |
Kcnt1抑制剂和使用方法
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
TWI770527B
(zh)
|
2019-06-14 |
2022-07-11 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
CN114340670A
(zh)
|
2019-07-11 |
2022-04-12 |
普拉克西斯精密药物股份有限公司 |
T-型钙通道调节剂的制剂及其使用方法
|
AU2020349553A1
(en)
|
2019-09-18 |
2022-04-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
AU2020351782A1
(en)
|
2019-09-26 |
2022-04-21 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
CN114727999A
(zh)
|
2019-11-26 |
2022-07-08 |
吉利德科学公司 |
用于预防hiv的衣壳抑制剂
|
MX2022006452A
(es)
|
2019-11-27 |
2022-07-11 |
Praxis Prec Medicines Inc |
Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.
|
WO2021155253A1
(en)
|
2020-01-31 |
2021-08-05 |
Atomwise Inc. |
Anat inhibitors and methods of use thereof
|
AU2021226747A1
(en)
|
2020-02-24 |
2022-09-01 |
Exelixis, Inc. |
Compounds and methods of use
|
US11697652B2
(en)
|
2020-02-24 |
2023-07-11 |
Gilead Sciences, Inc. |
Tetracyclic compounds and uses thereof
|
AU2021249010A1
(en)
|
2020-03-30 |
2022-10-06 |
Gilead Sciences, Inc. |
Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
|
BR112022019423A2
(pt)
|
2020-03-31 |
2022-12-06 |
Global Blood Therapeutics Inc |
Moduladores de hemoglobina
|
US20230159538A1
(en)
|
2020-04-01 |
2023-05-25 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
US10836757B1
(en)
|
2020-04-02 |
2020-11-17 |
Neurogastrx, Inc. |
Polymorphic forms of metopimazine
|
AU2021245924B2
(en)
|
2020-04-02 |
2024-02-29 |
Gilead Sciences, Inc. |
Process for preparing a Cot inhibitor compound
|
US20230212191A1
(en)
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
EP4143197A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
JP2023524033A
(ja)
|
2020-04-28 |
2023-06-08 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
フェロポルチン阻害剤としてのシクロアルキルピリミジン
|
WO2021222483A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
JP2023526235A
(ja)
|
2020-05-13 |
2023-06-21 |
プレリュード・セラピューティクス・インコーポレイテッド |
骨髄性細胞白血病-1(mcl-1)タンパク質の阻害剤としてのスピロ-スルホンアミド誘導体
|
US11702423B2
(en)
|
2020-06-09 |
2023-07-18 |
Prelude Therapeutics Incorporated |
BRM targeting compounds and associated methods of use
|
CA3181690A1
(en)
|
2020-06-25 |
2021-12-30 |
Chienhung CHOU |
Capsid inhibitors for the treatment of hiv
|
US20230278984A1
(en)
|
2020-08-03 |
2023-09-07 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
WO2022034474A1
(en)
|
2020-08-10 |
2022-02-17 |
Novartis Ag |
Treatments for retinal degenerative diseases
|
KR20230123919A
(ko)
|
2020-09-21 |
2023-08-24 |
프렐루드 테라퓨틱스, 인코포레이티드 |
Cdk 억제제 및 약제로서의 이의 용도
|
TW202222798A
(zh)
|
2020-09-30 |
2022-06-16 |
美商基利科學股份有限公司 |
橋接三環胺甲醯基吡啶酮化合物及其用途
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
CA3200685A1
(en)
|
2020-11-06 |
2022-05-12 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|
AU2021401403A1
(en)
|
2020-12-18 |
2023-07-13 |
Prelude Therapeutics Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
EP4267559A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
WO2022140325A1
(en)
|
2020-12-22 |
2022-06-30 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
CA3202944A1
(en)
|
2020-12-23 |
2022-06-30 |
David BAUMAN |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
PE20240687A1
(es)
|
2020-12-30 |
2024-04-10 |
Tyra Biosciences Inc |
Compuestos de indazol como inhibidores de cinasas
|
WO2022159387A1
(en)
|
2021-01-19 |
2022-07-28 |
Gilead Sciences, Inc. |
Substituted pyridotriazine compounds and uses thereof
|
WO2022170200A1
(en)
|
2021-02-08 |
2022-08-11 |
Global Blood Therapeutics, Inc. |
1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
|
TW202246283A
(zh)
|
2021-02-09 |
2022-12-01 |
美商基利科學股份有限公司 |
噻吩并吡咯化合物
|
WO2022178205A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
IL307203A
(en)
|
2021-04-16 |
2023-11-01 |
Gilead Sciences Inc |
THIENOPYRROLE COMPOUNDS
|
CA3219786A1
(en)
|
2021-05-14 |
2022-11-17 |
Global Blood Therapeutics, Inc. |
Solid forms of a modulator of hemoglobin
|
TW202304435A
(zh)
|
2021-06-04 |
2023-02-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2023279041A1
(en)
|
2021-06-30 |
2023-01-05 |
Tyra Biosciences, Inc. |
Indazole compounds
|
WO2023278843A2
(en)
|
2021-07-02 |
2023-01-05 |
Acer Therapeutics, Inc. |
Solid forms of osanetant
|
WO2023287787A1
(en)
|
2021-07-13 |
2023-01-19 |
Prelude Therapeutics, Incorporated |
Brm targeting compounds and associated methods of use
|
TW202313053A
(zh)
|
2021-07-30 |
2023-04-01 |
瑞士商艾克泰聯製藥有限公司 |
吡唑并嘧啶及其作為pdgfr抑制劑之用途
|
TW202325306A
(zh)
|
2021-09-02 |
2023-07-01 |
美商天恩治療有限公司 |
改良免疫細胞之生長及功能的方法
|
TW202327574A
(zh)
|
2021-09-10 |
2023-07-16 |
美商基利科學股份有限公司 |
噻吩并吡咯化合物
|
WO2023056441A1
(en)
|
2021-09-30 |
2023-04-06 |
Prelude Therapeutics Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
WO2023097234A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023102523A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
WO2023102239A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
US20230203071A1
(en)
|
2021-12-03 |
2023-06-29 |
Zhimin Du |
Therapeutic compounds for hiv virus infection
|
AU2022408097A1
(en)
|
2021-12-10 |
2024-05-30 |
Global Blood Therapeutics, Inc. |
Methods of administering a modulator of hemoglobin
|
US11939340B2
(en)
|
2022-01-21 |
2024-03-26 |
Prelude Therapeutics Incorporated |
CDK inhibitors and their use as pharmaceuticals
|
WO2023147312A1
(en)
|
2022-01-25 |
2023-08-03 |
Evvia Therapeutics, Inc. |
Ampk agonists and methods of use thereof
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023150612A1
(en)
|
2022-02-03 |
2023-08-10 |
Prelude Therapeutics, Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
US20240018136A1
(en)
|
2022-03-09 |
2024-01-18 |
Prelude Therapeutics, Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2023178547A1
(en)
|
2022-03-23 |
2023-09-28 |
Prelude Therapeutics, Incorporated |
Polymorphic compounds and uses thereof
|
US20240124422A1
(en)
|
2022-03-29 |
2024-04-18 |
Prelude Therapeutics Incorporated |
Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023220577A1
(en)
|
2022-05-10 |
2023-11-16 |
Prelude Therapeutics, Incorporated |
6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
|
WO2023225162A1
(en)
|
2022-05-20 |
2023-11-23 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
US20230399299A1
(en)
|
2022-06-14 |
2023-12-14 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2023244574A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
US20230416240A1
(en)
|
2022-06-16 |
2023-12-28 |
Prelude Therapeutics Incorporated |
Kat6 targeting compounds
|
WO2023247595A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
|
WO2023247593A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
|
WO2023247590A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
|
WO2023247596A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
TW202408493A
(zh)
|
2022-06-29 |
2024-03-01 |
美商泰拉生物科學公司 |
多晶形化合物及其用途
|
WO2024006897A1
(en)
|
2022-06-29 |
2024-01-04 |
Tyra Biosciences, Inc. |
Indazole compounds
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
WO2024047394A1
(en)
|
2022-08-31 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
|
US20240150340A1
(en)
|
2022-10-06 |
2024-05-09 |
Prelude Therapeutics Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
WO2024104968A1
(en)
|
2022-11-14 |
2024-05-23 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
|
WO2024107711A1
(en)
|
2022-11-15 |
2024-05-23 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|